Seattle Genetics has interim data for Adcetris in cutaneous T-cell lymphoma


Seattle Genetics is announcing interim results from an investigator-sponsored phase II clinical trial of the company's lead oncology product Adcetris® (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL). The results are being announced at the T-Cell Lymphoma Forum between January 26-28, 2012 in San Francisco.

23 patients were enrolled in the phase II trial, and 17 of them had received at least two doses of the antibody drug conjugate and therefore could be evaluated. These patients were diagnosed with relapsed CD30-positive cutaneous lymphoproliferative disorders, including:

-- Lymphomatoid papulosis (LyP)
-- Primary cutaneous anaplastic large cell lymphoma (pcALCL)
-- Mycosis fungoides (MF)

Of the 17 patients, 11 of them or 65 % achieved an objective response, including seven complete remissions (CRs) and four partial remissions (PRs). Six patients had stable disease.

Source: MarketWatch

LymphomaInfo Social